论文部分内容阅读
目的探讨硼替佐米联合地塞米松治疗多发性骨髓瘤患者的临床疗效。方法 50例多发性骨髓瘤患者,按照治疗方法不同分为观察组和对照组,每组25例。观察组患者给予硼替佐米联合地塞米松进行治疗,对照组患者给予长春新碱、地塞米松和左旋苯丙氨酸氮芥进行治疗。观察比较两组患者治疗后的临床疗效和不良反应情况。结果治疗后,观察组患者中完全缓解14例,接近完全缓解6例,部分缓解3例,轻微反应1例,无改变1例,疾病进展0例,总有效率为92%。对照组患者中完全缓解9例,接近完全缓解5例,部分缓解2例,轻微反应4例,无改变3例,疾病进展2例,总有效率为64%。观察组总有效率明显高于对照组,差异具有统计学意义(P<0.05);观察组总不良反应发生率(52%)明显低于对照组(72%),差异具有统计学意义(P<0.05)。结论硼替佐米联合地塞米松治疗多发性骨髓瘤,临床疗效显著,不良反应发生率比较低,值得临床广泛推广。
Objective To investigate the clinical efficacy of bortezomib combined with dexamethasone in patients with multiple myeloma. Methods Fifty patients with multiple myeloma were divided into observation group and control group according to different treatment methods, with 25 cases in each group. Patients in the observation group were treated with bortezomib plus dexamethasone, and patients in the control group were treated with vincristine, dexamethasone and melphalan. The clinical efficacy and adverse reactions of the two groups after treatment were observed and compared. Results After treatment, 14 cases were completely relieved in the observation group, 6 cases were near complete remission, 3 cases were partial remission, 1 case was slight reaction, 1 case was unchanged, 0 case was disease progression, and the total effective rate was 92%. In the control group, 9 patients were completely relieved, 5 were nearly complete remission, 2 were partially relieved, 4 were mild, 3 were unchanged, 2 were disease progression. The total effective rate was 64%. The total effective rate in the observation group was significantly higher than that in the control group (P <0.05). The incidence of adverse reactions in the observation group (52%) was significantly lower than that in the control group (72%), the difference was statistically significant (P <0.05). Conclusion Bortezomib combined with dexamethasone in the treatment of multiple myeloma, a significant clinical effect, the incidence of adverse reactions is relatively low, worthy of widespread clinical promotion.